Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies.
04/10/11Neuralstem shares jump over 13% on new stem cell patent
16/12/10Neuralstem Receives FDA Approval to Start Phase Ia Trial for Depression Drug
14/09/10Study Shows Neuralstem’s Stem Cells May Have Application To Treating Stroke
Recent Sector News
U.S. stock market futures shifted lower on Tuesday as investors look for more clues on any tapering of the Federal Reserve’s easing program. Two Fed presidents with voting rights on the interest-rate setting committee are due to speak later in the day. Futures for the Dow industrials rose less than 0.1 percent to 15,323,00 while those for the Standard & Poor’s 500 index was little changed at 1,664.60 and the Nasdaq 100 index futures slipped less than 0.1 percent to 3,018.25.
U.S. markets rose on Friday after positive economic reports that boosted investor sentiment to recover losses from the previous session, with benchmark indexes set to record their fourth straight week of gains and close at another set of record highs.
With a fresh round of financing at its disposal, Sirona Biochem (CVE: SBM) is poised to follow through with its strategy of pursuing patent opportunities, partners and joint ventures. Earlier this month, the Vancouver-based biotechnology firm announced it had raised nearly $1 million, which brings its total debt and equity financing to $2.4 million so far this year.
Soligenix (OTCQB:SNGX), a biopharmaceutical company focused on products for inflammatory diseases and biodefense countermeasures, has taken yet another step toward advancing one of its drugs, saying it has started the first clinical study for the development of SGX203, its treatment for pediatric Crohn's disease.
Pivotal Therapeutics says Vascazen product can correct Omega-3 deficiency in patients with heart disease
Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO), a specialty pharmaceutical company focused on Omega-3 therapies for cardiovascular disease (CVD), revealed today results from its Vascazen "Reveal" clinical trial, saying the product was "highly effective" in correcting an Omega-3 deficiency.
U.S. stock futures rose slightly on Tuesday amid corporate earnings and ahead of consumer credit data, looking set to extend gains that took benchmark indexes to record highs in the previous session.
Investors interested in Neuralstem recently viewed
- Hemispherx BioPharma (NYSE AMEX: HEB) Clinical development and manufacture of products for medical conditions
- Medgenics (AMEX , AIM: MDGN) Developing "Biopump" technology for the treatment of chronic diseases
- Pivotal Therapeutics (CNSX, OTCQX: PVO) Extracting the Science and Formulating Superior Therapeutics
- Epistem (AIM: EHP) Biotechnology company applying its expertise in epithelial stem cells
- Cellmid (ASX: CDY) Cellmid is the world leader in Midkine Intellectual Property